Smart pen could make insulin dosing easier for teens with diabetes

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients from 13-21 years of age (inclusive) at the time of enrollment. 2. Patients diagnosed with type 1 diabetes for more than 6 months. 3. Patients with uncontrolled T1D as defined by an elevated HbA1c \> 8% within the last 3 months prior to the start of the study. 4. Patients using multiple daily injections of insulin (MDI); basal- bolus regimen requiring three or more injections per day. 1. Basal insulin requirement: one or two dose per day of a long-acting insulin analog: insulin glargine U-100 (Lantus or Basaglar), insulin glargine U-300 (Toujeo), insulin detemir (Levemir), or insulin degludec (Tresiba). 2. Bolus insulin requirement: three or more doses per day of a rapid-acting insulin analog: insulin lispro (Humalog or Admelog) or insulin aspart (Novolog or Fiasp). 5. Completion of basic diabetes education program within first year of diagnosis including management of hyperglycemia and hypoglycemia. 6. Patients not actively using InPen (including discontinuation of the InPen for at least 12 weeks). Exclusion Criteria: 1. Pediatric patients with T1D with health conditions that may impact glycemic control (e.g., uncontrolled hypothyroidism or hyperthyroidism or prolonged use (more than 2 weeks) of exogenous steroids), pregnancy, language barrier, or inability to obtain informed consent from patient and/or caregiver. 2. Patients who are unable to obtain insurance approval to cover the cost for the InPen device and insulin cartridges for the InPen. 3. Patients with T1D who are allergic to Humalog and Novolog insulin analogs. 4. Patients/caregivers who are unwilling to switch to the InPen device and/or insulin cartridges required for the use of the InPen device. 5. Patients who do not own a smartphone or tablet that is compatible with the InPen App.